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Summary
Background: Sorafenib was tested for neoadjuvant treat-
ment with an anthracycline/taxane-based chemotherapy 
in the open-label, multicentre, single-arm phase II study, 
‘SOFIA’. Patients and Methods: Inclusion criteria were: 
HER2 negative, cT3, cT4 or cT2 cN+, M0 primary breast 
cancer. Patients received 4 × epirubicin 90 mg/m2 and 
 cyclophosphamide 600 mg/m2 (EC) intravenously (i.v.) in 
3-weekly cycles followed or preceded by 12 weeks of pa-
clitaxel (Pw) 80 mg/m2. In cohort 1, sorafenib started at 
800 mg daily with chemotherapy. An initial daily sorafenib 
dose of 200 mg was escalated, based on individual tox-
icities, every 3 weeks in cohort 2 (starting with EC) and 
every 2 weeks in cohort 3 (starting with Pw). The primary 
objective was to identify the most feasible regimen; sec-
ondary objectives were safety, pathological complete re-
sponse (pCR) at surgery and pharmacokinetics. Results: 
Of the 36 recruited patients, 7/12 patients completed the 
study in cohort 1 and 24/24 patients in cohorts 2 and 3. 
The median cumulative sorafenib dose per patient was 
37%, 65% and 46% in cohorts 1, 2 and 3, respectively. 
The main grade 3–4 toxicities were neutropenia and 
hand-foot syndrome. The pCR (ypT0/is) rate was 27.7%. 
No pharmacokinetic interaction was observed between 
sorafenib and epirubicin. Conclusion: Sorafenib EC-Pw is 
feasible if the starting dose is 200 mg, escalated every 
3 weeks based on the patients’ individual toxicities.
Introduction
The vascular endothelial growth factor (VEGF) receptor 
plays an important role in tumour vascularisation and growth. 
Bevacizumab, an anti-VEGF antibody, has improved progres-
sion-free survival of metastatic breast cancer when added to 
various chemotherapy regimens [1]. In combination with 
 anthracycline/taxane-based chemotherapy given preopera-
tively, bevacizumab significantly increased the pathological 
complete response (pCR) rate in early breast cancer [2, 3].
Sorafenib, a potent multikinase inhibitor, targets the 
VEGF-2 receptor, the platelet-derived growth factor recep-
tor-b (PDGFR-b), but also the Raf kinase, c-Kit and Flt [4]. 
Preclinical studies demonstrated antitumor activity independ-
ent of Ras mutations and suggested additive anti-tumour 
 effects [5]. 2 phase II studies including 79 heavily pretreated 
breast cancer patients revealed only modest single-agent ac-
tivity but good tolerability [6, 7]. A subsequent randomised 
phase II study in 229 human epidermal growth factor receptor 
2 (HER2)-negative metastatic breast cancer patients investi-
gated the combination of sorafenib and capecitabine. The ad-
dition of sorafenib to capecitabine resulted in a significant 
improvement in progression-free survival versus placebo 
 (median, 6.4 vs. 4.1 months; hazard ratio (HR), 0.58; 95% 
confidence interval (CI), 0.41–0.81; P = 0.001), favouring 
sorafenib across subgroups, but was associated with higher 
toxicity and treatment discontinuation [8]. A randomised 
phase III study (RESILIENCE; NCT01234337) currently as-
sesses this concept [9].
The neoadjuvant systemic treatment of breast cancer yields 
disease-free and overall survival rates comparable to those 
with adjuvant systemic therapy but allows for treatment moni-
toring in previously untreated patients [10]. Before any other 
combination therapy was explored, the non-randomised 
phase II SOFIA study (NCT00548899) was started to investi-
gate the addition of sorafenib to standard epirubicin and 
 cyclophosphamide (EC)-paclitaxel weekly chemotherapy 
*The study was previously presented in an oral presentation at the  
8th European Breast Cancer Conference (EBCC-8), 21–24 March 2012, 
in Vienna and as a poster at the 34th Annual Meeting of the American 
Society of Clinical Oncology, 1–5 June 2012, in Chicago.
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ing sensory neuropathy grade ≥ 2 (National Cancer Institute Common Tox-
icity Criteria v. 3.0 (NCI-CTC)), no major surgery within the past 4 weeks, 
no other serious illnesses or medical conditions. The study adhered to the 
Declaration of Helsinki. The protocol was reviewed by the responsible 
 ethics committee at each participating site. The conduct of the trial was 
 supervised by an independent data and safety monitoring committee.
Therapy
All patients received neoadjuvant EC (epirubicin 90 mg/m2 plus 
 cyclo phosphamide 600 mg/m2 body surface area) once every 3 weeks for 
4 cycles, followed or preceded by paclitaxel 80 mg/m2 every week for 
12 weeks. In cohort 1, patients received a fixed oral daily dose of 800 mg 
sorafenib on days 2–19 during EC and continuously during paclitaxel. 
Sorafenib was stopped after 23 weeks of treatment. This would result in a 
cumulative dose of 119.2 g sorafenib. After an amendment due to in-
creased skin toxicities (any type) resulting in therapy discontinuation, 
 patients in cohorts 2 and 3 started with sorafenib 200 mg daily and 
 increased the dose during EC every cycle and during paclitaxel every 2 
weeks if no skin toxicity occurred. In case of skin toxicity grade 1, the same 
dose was continued. The maximum achieved dose was maintained through-
out the treatment. In cohort 3, patients started with paclitaxel f ollowed by 
EC using the same dose-escalating schedule for sorafenib (supplementary 
fig. S1). All patients were then operated on and received adjuvant radio-
therapy and endocrine treatment as standard of care if indicated.
Pharmakokinetics
During EC treatment, pharmacokinetic samples were taken during 
 cycles 1 and 2 (alternatively 3) on day 1 prior to the start of epirubicin 
 infusion, at the termination of epirubicin infusion and at 5, 20, 180 min 
and 24 h after the end of epirubicin infusion. Population pharmacokinetic 
analyses on total epirubicin concentrations quantified by a previously 
published high-performance liquid chromatography (HPLC) method 
were carried out using NONMEM 7.2 (ICON Development Solutions, 
Dublin, Ireland) [12].
as neo adjuvant treatment in medium-to-high-risk primary 
HER2-negative breast cancer [11].
Methods and Patients
Objectives
The primary objective of this open-label, single-arm, multicentre 
phase II study was to find the most feasible regimen of sorafenib (i.e. the 
regimen with the highest cumulative dose of sorafenib) in combination 
with epirubicin, cyclophosphamide and paclitaxel in patients with HER2-
negative primary breast cancer. Secondary end points were tolerability, 
pCR rate after neoadjuvant chemotherapy with sorafenib, the response 
rates of breast tumours and axillary nodes as assessed by palpation or 
 ultrasonography before surgery, the rates of pathological stage ypN0 after 
neoadjuvant therapy and the rate of breast conservation (for methods, 
see supplementary material). Pharmacokinetic interaction of sorafenib 
and epirubicin was assessed additionally.
Patients
Women with histologically confirmed uni- or bilateral primary 
 untreated breast cancer who provided written informed consent were 
 eligible. The HER2 status of the tumour had to be negative. The tumour 
had to be at least 2 cm in size by palpation and measurable preferably by 
ultrasound. In case of inflammatory breast cancer, the extension of the 
inflammation could be used as measurable lesion. Patients should have a 
disease stage in which adjuvant chemotherapy would be considered; 
therefore, the following stages were eligible: locally advanced disease 
with cT3–T4 or cT2, cN+. Further relevant criteria were a normal cardiac 
function measured by echocardiography (left ventricular ejection fraction 
≥ 55%), no known thromboembolic events or ischemic attacks in the pre-
vious 6 months, no haemorrhagic diathesis or coagulopathy, no pre-exist-
Table 1. Baseline characteristics
Cohort 1 (N = 12) Cohort 2 (N = 12) Cohort 3 (N = 12) Total (N = 36)
Age, years: median (range) 44 (31–67) 44 (28–53) 47 (28–56) 45 (28–67)
Menopausal status
Pre  9 (75.0%) 12 (100%)  8 (66.7%) 29 (80.6%)
Post  3 (25%)  0 (0%)  4 (33.3%)  7 (19.4%)
Karnofsky score
100% 11 (91.7%) 12 (100.0%) 10 (83.3%) 33 (91.7%)
 90%  1 (8.3%)  0 (0.0%)  2 (16.7%)  3 (8.3%)
Clinical T stage
I  0 (0%)  2 (16.7%)  4 (33.3%)  6 (16.7%)
II 11 (91.7%) 10 (83.3%)  6 (50.0%) 27 (75.0%)
III  1 (8.3%)  0 (0%)  2 (16.7%)  3 (8.3%)
Clinical N stage
0  3 (25.0%)  8 (66.7%)  6 (50.0%) 17 (47.2%)
1  9 (75.0%)  4 (33.3%)  6 (50.0%) 19 (52.8%)
2  0 (0.0%)  0 (0.0%)  0 (0.0%)  0 (0.0%)
Sentinel node biopsy
Yes  2 (16.7%)  4 (33.3%)  5 (41.7%) 11 (30.5%)
No 10 (83.3%)  8 (66.7%)  7 (58.3%) 25 (69.5%)
Histological tumour type
Ductal or ductal/lobular invasive  9 (75.0%) 10 (83.3%) 11 (91.7%) 30 (83.3%)
Lobular invasive  0 (0.0%)  1 (8.3%)  1 (8.3%)  2 (5.6%)
Other  3 (25.0%)  1 (8.3%)  0 (0.0%)  4 (11.1%)
Tumour grade
I  1 (8.3%)  0 (0.0%)  0 (0.0%)  1 (2.8%)
II  4 (33.3%)  6 (50.0%)  6 (50.0%) 16 (44.4%)
III  7 (58.3%)  6 (50.0%)  6 (50.0%) 19 (52.8%)
Hormone receptor status
Positive  8 (66.7%)  6 (50.0%)  7 (58.3%) 21 (58.3%)
Negative  4 (33.3%)  6 (50.0%)  5 (41.7%) 15 (41.7%)
HER2 status
Negative 12 (100%) 12 (100%) 12 (100%) 36 (100%)




All patients who started therapy were included in the efficacy and 
safety analyses. Patients with missing data regarding response were 
counted as having no response.
The initial sample size calculation was based on the GeparDuo study 
[13]. An exact binominal test with an alpha of 10% would have had an 
80% power to detect the difference between the null hypothesis propor-
tion (pCR of 25% (22.3%)) and the alternative proportion (pCR of 40%) 
when the sample size was 62 patients. The original primary end point 
pCR was modified by an amendment to find the most feasible regimen 
for sorafenib (i.e. the regimen with the highest cumulative dose of 
sorafenib), as an early safety assessment revealed that tolerability of the 
initial schedule was not given, and 3 equal-sized cohorts with 12 patients 
each were recruited to establish the best regimen.
Results
Patients
From November 2007 until December 2010, 36 patients 
(12 in each cohort) entered the study in 10 sites in Germany. 
The baseline characteristics overall and per treatment cohort 
are outlined in table 1.
Compliance and Toxicity
The 36 patients were distributed into 3 equal-sized cohorts. 
All patients received 4 cycles of EC, and 33 patients received 
12 weeks of paclitaxel. 1 patient never started paclitaxel, 1 pa-
tient stopped after 6 weeks and 1 after 9 weeks. 18 patients 
received at least 23 weeks of sorafenib as planned (supple-
mentary table S1). In cohort 1, 7 of 12 patients completed the 
study and 6 of them received sorafenib at a reduced dose; 
5 patients discontinued sorafenib prematurely, 3 due to ad-
verse events, 1 due to progression and 1 on the patient’s re-
quest. In cohort 1, the maximum tolerated dose of sorafenib 
was 400 mg per day. Only 1 patient could be treated with 
800 mg sorafenib daily. In cohorts 2 and 3, all 12 patients 
 completed the study. In cohort 2, the sorafenib dose could be 
escalated to 800 mg in 6 of the 12 patients, to 600 mg in 4 pa-
tients and to 200 mg daily in 2 patients. In cohort 3, 1 patient 
was escalated to 800 mg, 3 to 600 mg, 6 to 400 mg and 2 pa-
tients remained on 200 mg sorafenib daily. The median cumu-
lative dose per patient was 44.5 g in cohort 1, 77.4 g in cohort 
2 and 55.2 g in cohort 3, which corresponds to 37%, 65% and 
46% relative to the maximum pre-planned cumulative dose of 
800 mg, respectively.
The main toxicities were neutropenia grade 3–4 in all pa-
tients and hand-foot syndrome (HFS) of any grade in 30/36 
patients, which was severe in 5 patients (table 2). Sensory 
neuropathy grade 1–2 was reported in 26 patients. Nausea and 
vomiting grade 1–2 were observed in 32 and 12 patients, re-
spectively. 1 patient had severe nausea. No patient died while 
on treatment.
Table 2. Adverse events per patient
Cohort 1 (N = 12) Cohort 2 (N = 12) Cohort 3 (N = 12) Overall (N = 36)
Toxicity, grade  1–4  3–4  1–4  3–4  1–4  3–4  1–4  3–4
Hematologic toxicity, n
Leukopenia 12 10 12 10 11  8 35 28
Neutropenia 12 11 12 12 12 12 36 35
Febrile neutropenia  0  0  1  1  2  2  3  3
Anaemia 12  0 12  0 12  1 36  1
Thrombopenia  2  0  5  0  5  1 12  1
Non-haematologic toxicity, n
Alopecia 12 n.a. 12 n.a. 12 n.a. 36 n.a.
Allergic reaction  5  1  2  1  4  1 11  3
Conjunctivitis  2  0  0  0  2  0  4  0
Diarrhoea  9  0 12  0  9  0 30  0
Dyspnoea  1  0  1  0  4  0  6  0
Fatigue  9  0  9  0 12  1 30  1
Fever without neutropenia  0  0  2  1  5++  1  7  2
Flu and flu-like symptoms  5  1  4  0  6  2 15  3
Haemorrhage  6  0 11  0 10  0 27  0
Hypertension  4  0  4  0  3  0 11  0
Infection without neutropeniaa  4 n.a.  0 n.a.  3 n.a.  7 n.a.
Mucositis  8  0 11  0 10  1 29  1
Nail changes  6  0  3  0  7  0 16  0
Nausea 10  1 11  0 11  0 32  1
Oedema  3  0  2  0  5  0 10  0
Pain 10  1  8  0 10  0 28  1
Thromboembolic event  3  2  2  0  2  2  7  4
Skin toxicity (all events)b 31  8 26  1 34  1 92 11
Hand-foot syndrome 11  4  9  1 10  0 30  5
Skin rash/acne  9  2  8  0 12  1 29  3
Pruritus  3  0  3  0  5  0 11  0
Erythema  5  2  1  0  4  0 10  2
Dry skin  3  0  5  0  3  0 11  0
Sensory neuropathy  5  0 10  0 11  0 26  0
Vomiting  7  0  4  0  1  0 12  0
aIncluded local and systemic infections. b1 patient could have experienced more than 1 event. n.a. = not applicable.
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derived from the population pharmacokinetic evaluation was 
2,880 ± 870 ng/ml/h. Cmax was calculated as 1,400 ± 800 ng/ml. 
Individual estimates of the concentration-versus-time profile 
of the population are shown in figure 1. More detailed infor-
mation on model development and validation is shown in the 
supplementary data (supplementary figs. S3 and S4). It could 
be demonstrated that sorafenib has no major effect on the 
epirubicin pharmacokinetics for the treatment schedule used.
Discussion
SOFIA is the first study evaluating sorafenib in the neo-
adjuvant setting in patients with primary breast cancer using 
a standard anthracycline/taxane-based chemotherapy regi-
men. The starting dose of sorafenib was 400 mg twice daily 
(800 mg) [14]. After the first 12 patients had been recruited, 
the starting dose of 800 mg sorafenib daily was reduced to 
200 mg and an individual dose escalation scheme was imple-
mented. This approach of individual dose escalation of 
sorafenib within a standard sequential chemotherapy of EC 
and weekly paclitaxel was necessary to reduce treatment 
 discontinuation of sorafenib from 42% in cohort 1 to 0% in 
cohorts 2 and 3. This resulted in a higher cumulative sorafenib 
dose. It seems that the dose escalation was more feasible 
when starting with EC than with weekly paclitaxel, leading to 
a higher median dose of sorafenib and more patients achiev-
ing 800 mg. This could be due to the fact that in cohort 2 the 
dose escalation was performed every 3 weeks and in cohort 3 
every 2 weeks. Non-haematologic side effects were mainly of 
low grade; 83% of the patients reported HFS, which was 
 severe in 5 patients. HFS was less frequent in cohorts 2 and 3, 
despite achieving a higher cumulative dose of sorafenib, 
which was reported to be associated with increased hand-foot 
skin toxicity [15].
In an adjuvant phase II study for primary breast cancer, 
 patients received doxorubicin 60 mg/m2 and cyclophospha-
mide 600 mg/m2 (AC) every 3 weeks, followed by paclitaxel 
175 mg/m2 intravenously on day 1 every 3 weeks for 4 cycles 
or 80 mg/m2 for 12 weeks (physician’s discretion), combined 
with sorafenib 400 mg orally twice daily. Sorafenib was con-
tinued for a total of 12 months and in combination with adju-
vant hormonal therapy where indicated [16]. Of the 45 pa-
tients recruited, only 14 (31%) completed the chemotherapy-
plus-sorafenib treatment phase, entered the maintenance 
phase and continued up to 15 weeks; 2 patients completed 
paclitaxel plus sorafenib but did not enter the maintenance 
phase. 60% of the patients stopped treatment prematurely 
 either due to toxicity or due to the physician’s/patient’s 
 decision. Toxicities were mainly of low grade and included 
neutropenia, anorexia, arthralgia, diarrhoea, and dyspnoea. In 
the metastatic setting, the addition of sorafenib to either 
capecitabine or paclitaxel resulted in higher rates of adverse 
events for the combination therapy compared to chemo-
Efficacy
A total of 10 patients had a pCR (ypT0/is) (27.8%, 95% CI 
13.1–42.3%). If nodal involvement was considered for pCR 
definition, 9 patients (25.0%) had no invasive residuals in the 
breast and no involved lymph nodes (ypT0/Tis, ypN0) and 
8 patients (22.2%) had no invasive and no non-invasive 
 residuals in breast and nodes (ypT0/ypN0). Overall, 15 pa-
tients had triple-negative breast cancer (TNBC), 6 of whom 
achieved a pCR (40.0%, 95% CI 15.2–64.8%). From the total 
of 36 patients, 14 (38.9%) were treated with mastectomy.
After a median follow-up of 3.9 years (range 3.1–4.5 years), 
five relapses and 2 deaths were observed.
Pharmacokinetics Results
Samples from 23 patients were available. Absolute epi-
rubicin doses of 160 ± 16 mg (mean ± standard deviation 
(SD)) were infused over 1.1 ± 0.8 h. The pharmacokinetics of 
epirubicin was best described by a 3-compartment model with 
linear elimination (supplementary fig. S2), with a terminal 
half-life of 23.9 h. The pharmacokinetic parameter estimates 
and their CIs of a bootstrap analysis (1000 runs) are summa-
rised in table 3. The average area under the curve (AUC) as 
Table 3. Parameter estimates and their bootstrap CIs  
from the pharmacokinetic model
Parameter Estimate (95% CI) Literaturea
V1, l 15.2 (11.2–21.5) 10.3
V2, l 51.8 (26.8–99.5) 35.7
V3, l 1070 (826–1990) 772
CL1, l/h 55.9 (35.2–65.5) 72.9
CL2, l/h 26.9 (17.5–42.0) 30.2
CL3, l/h 73.8 (58.8–103) 61.5
aValues taken from [25]. 
V = Volume, CL = clearance.
Fig. 1. Individual estimates of epirubicin concentrations (ng/ml) versus 
time (h) of the first period, based on the population pharmacokinetic 
model.
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added effect. The failure of bevacizumab to prolong disease-
free and overall survival has tempered expectations for the 
success of anti-angiogenic tyrosine kinase inhibitors [26, 27]. 
Nevertheless, these anti-VEGF compounds certainly have 
 activity, and translational work to identify the subgroups of 
responsive patients will be critical [28]. The lack of success of 
anti-angiogenic therapies in breast cancer to date may in part 
be explained by activation of additional pro-angiogenic 
switches upon blockade with bevacizumab, as has been shown 
in experimental systems [29].
The main limitation of our study is that the initial protocol 
was not feasible, resulting in a low recruitment probably due 
to low acceptance of the combination and more attractive 
competing trials. The 3 different treatment approaches gener-
ated feasibility data of the combination of EC and paclitaxel 
in combination with sorafenib. Paclitaxel weekly as single 
agent was thought to allow for a more rapid dose escalation of 
sorafenib every 2 weeks, which could not be proven.
In conclusion, a dose of 800 mg sorafenib as it is given as 
single agent in metastatic breast cancer and renal cell cancer 
was not tolerated as a starting dose in combination with stand-
ard anthracycline/taxane-based chemotherapy in early breast 
cancer. Sorafenib can be combined with epirubicin without 
drug-drug interactions, and an individual dose escalation 
model starting from 200 mg was feasible, resulting in signifi-
cantly higher cumulative doses of sorafenib compared to a 
fixed starting dose and in no treatment discontinuations.
Online Supplemental Material
Table S1. Summary of maximum treatment cycles per drug and cohort
Figure S1. Study Design and Dose escalation model.
Figure S2. Pharmacokinetic model for the prediction of epirubicin 
 plasma concentrations after infusion.
Figure S3. Population predicted epirubicin concentrations versus observed 
concentrations
Figure S4. Individual predicted epirubicin concentrations versus observed 
concentrations.
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therapy alone. Main grade 3–4 toxicities with paclitaxel plus 
sorafenib versus placebo were neutropenia (13% vs. 7%), 
anaemia (11% vs. 6%) and HFS (31% vs. 3%) [17]. In the 
capecitabine study, grade 3–4 toxicities were higher only for 
HFS (44% vs. 14%) when sorafenib was added, and any-
grade toxicities were significantly higher mainly for HFS 
(90% vs. 14%), rash (22% vs. 8%), diarrhoea (58% vs. 30%), 
neutropenia (13% vs. 4%) and hypertension (18% vs. 12%). 
20% compared to 9% of the patients in the control arm 
stopped the treatment prematurely due to toxicity.
This demonstrated that the 800-mg daily dose used for 
sorafenib as monotherapy is not feasible in combination with 
chemotherapy and therefore treatment modifications that are 
associated with a higher compliance rate have to be explored. 
One of these actions to increase compliance with the oral 
therapy with sorafenib can be a dose escalation based on the 
individual patient’s toxicities, as explored here. The phase III 
RESILIENCE study [9] investigating the combination of 
sorafenib and capecitabine starts sorafenib at 600 mg daily 
and capecitabine at 2000 mg/m2 on days 1–14 of a 21-day 
cycle, but allows both drugs to be escalated based on individ-
ual toxicities related to the treatment. The dose of sorafenib 
was based on the preceding phase II study with a mean daily 
dose per patient of 584 mg [8]. Capecitabine 2000 mg/m2 is a 
well-tolerated and highly effective therapy [18]. In summary, 
dermatologic toxicities – especially hand-foot (skin) syndrome 
or reactions – are among the main reasons to stop or reduce 
multikinase targeting agents such as sorafenib, especially 
when combined with a chemotherapy inducing similar toxici-
ties [19]. This has, for example, been shown in the case of 
 sunitinib [20, 21], which was consequently stopped for further 
development in breast cancer.
Based on early reports of possible drug-drug interactions 
of anthracyclines with sorafenib and taking into account the 
long mean half-life of sorafenib, which is about 24–48 h [22], 
pharmacokinetic data for epirubicin were collected [23]. The 
epirubicin concentration time profile was successfully de-
scribed by a 3-compartment pharmacokinetic model, whereas 
a 2-compartment model, which has also been reported [24], 
was not sufficient to describe the data. The parameter esti-
mates for the final model are very similar to those published 
in the literature for another 3-compartment model of epi-
rubicin, suggesting that sorafenib has no major effect on the 
epirubicin pharmacokinetics in the treatment schedule used 
[25].
The pCR rate, defined as no invasive residuals in the 
breast, was 27.8%, which is comparable to 24.5% (21.9–
27.4%) reached with bevacizumab in addition to EC followed 
by docetaxel in the GeparQuinto study, but slightly lower 
than 34.5% (30.7–38.3%) in the National Surgical Adjuvant 
Breast and Bowel Project (NSABP) B40 study [2, 3]. The 
pCR rates, irrespective of the definitions, were slightly above 
those seen with bevacizumab [2, 3]. However, the sample size 
was smaller than initially planned in order to demonstrate an 
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